Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021
February 04, 2022 14:00 ET
|
Infant Bacterial Therapeutics AB
Press release February 4, 2022 Message from the CEO IBT’s ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities of premature infants. This is...
The Connection Study fortsätter efter planerad säkerhetsanalys av Data Monitoring Committee (DMC)
January 19, 2022 17:30 ET
|
Infant Bacterial Therapeutics AB
Den 30 september, 2021 meddelade Infant Bacterial Therapeutics (IBT) att företaget nått en viktig milstolpe i utvecklingen av IBP-9414, efter att ha rekryterat 600 för tidigt födda barn till The...
The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
January 19, 2022 17:30 ET
|
Infant Bacterial Therapeutics AB
On September 30, 2021 Infant Bacterial Therapeutics (IBT) announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The...
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Australien
January 10, 2022 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att patentverket i Australien utfärdat ett godkännande för patentet: “A method of activating lactic acid bacteria”, vilket omfattar formuleringar...
Infant Bacterial Therapeutics today announces that new patent protection is granted in Australia
January 10, 2022 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of...
Infant Bacterial Therapeutics tillkännager idag att nya patent har godkänts i Brasilien samt i Hong Kong
December 27, 2021 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att patentverken i Brasilien och Hong Kong har godkänt ett patent för Lactobacillus reuteri som omfattar IBP-9414. IBP-9414 är den...
Infant Bacterial Therapeutics today announces new patent protection approvals in Brazil and in Hong Kong
December 27, 2021 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB today announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug...
Infant Bacterial Therapeutics CFO lämnar bolaget
December 10, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs Chief Financial Officer (CFO) Marie Louise Alamaa har idag lämnat IBT för att anta nya utmaningar. IBTs Controller, Michael Owens, har samtidigt tillträtt som ny...
Infant Bacterial Therapeutics CFO leaves the company
December 10, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs CFO Marie Louise Alamaa left the company to pursue new opportunities. IBT’s Controller, Michael Owens, has assumed the responsibility of CFO moving forward. “I would...
EN BLINDAD UTVÄRDERING AV IBT:S CONNECTION STUDY – “SUSTAINED FEEDING TOLERANCE” (SFT) KORRELERAR MED KLINISKA UTFALL
December 06, 2021 13:47 ET
|
Infant Bacterial Therapeutics AB
En blind utvärdering av IBTs Connection Study kommer att presenteras av Professor Josef Neu, University of Florida, vid 2021 Hot Topics in Neonatology® den 6 december 2021. Utvärderingen avslöjar att...